UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
NRSN holding history
NeuroSense Therapeutics Ltd. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NRSN overviewAll 13F holders of NRSNFull Q2 2026 holdings
- Shares (Q2 2026)
- 108,636
- Value
- $78.2K
- % of portfolio
- <0.1%
- Quarters held
- 15
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 108,636 | $78.2K | <0.1% | +59,540+121.3% | Added | Holders |
| Q1 2026 | 49,096 | $37.1K | <0.1% | +18,225+59.0% | Added | Holders |
| Q4 2025 | 30,871 | $23.7K | <0.1% | +16,212+110.6% | Added | Holders |
| Q3 2025 | 14,659 | $18.3K | <0.1% | +13,048+809.9% | Added | Holders |
| Q2 2025 | 1,611 | $3.04K | <0.1% | −664−29.2% | Reduced | Holders |
| Q1 2025 | 2,275 | $2.12K | <0.1% | +2,275 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −11,928−100.0% | Sold out | Holders |
| Q1 2024 | 11,928 | $21.7K | <0.1% | +6,432+117.0% | Added | Holders |
| Q4 2023 | 5,496 | $4.31K | <0.1% | −4,169−43.1% | Reduced | Holders |
| Q3 2023 | 9,665 | $6.86K | <0.1% | +9,665 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −4,762−100.0% | Sold out | Holders |
| Q1 2023 | 4,762 | $8.19K | <0.1% | +697+17.1% | Added | Holders |
| Q4 2022 | 4,065 | $4.96K | <0.1% | +2,238+122.5% | Added | Holders |
| Q3 2022 | 1,827 | $3.00K | <0.1% | −11,601−86.4% | Reduced | Holders |
| Q2 2022 | 13,428 | $45.0K | <0.1% | +11,544+612.7% | Added | Holders |
| Q1 2022 | 1,884 | $7.00K | <0.1% | −6,134−76.5% | Reduced | Holders |
| Q4 2021 | 8,018 | $20.0K | <0.1% | +8,018 | New | Holders |